[go: up one dir, main page]

SG11202110972UA - Anti-vegf protein compositions and methods for producing the same - Google Patents

Anti-vegf protein compositions and methods for producing the same

Info

Publication number
SG11202110972UA
SG11202110972UA SG11202110972UA SG11202110972UA SG11202110972UA SG 11202110972U A SG11202110972U A SG 11202110972UA SG 11202110972U A SG11202110972U A SG 11202110972UA SG 11202110972U A SG11202110972U A SG 11202110972UA SG 11202110972U A SG11202110972U A SG 11202110972UA
Authority
SG
Singapore
Prior art keywords
producing
methods
same
protein compositions
vegf protein
Prior art date
Application number
SG11202110972UA
Inventor
Shunhai Wang
Ning Li
Hunter Chen
Bhalla Amardeep Singh Bhupender
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202110972U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202110972UA publication Critical patent/SG11202110972UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
SG11202110972UA 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same SG11202110972UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046846 WO2021112928A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
SG11202110972UA true SG11202110972UA (en) 2021-10-28

Family

ID=76210828

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11202110955VA SG11202110955VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110958QA SG11202110958QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110953UA SG11202110953UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110968VA SG11202110968VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110964QA SG11202110964QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110972UA SG11202110972UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Family Applications Before (5)

Application Number Title Priority Date Filing Date
SG11202110955VA SG11202110955VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110958QA SG11202110958QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110953UA SG11202110953UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110968VA SG11202110968VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110964QA SG11202110964QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Country Status (19)

Country Link
US (36) US11186625B2 (en)
EP (11) EP3906249A1 (en)
JP (13) JP2022548818A (en)
KR (13) KR20240007293A (en)
CN (6) CN114206914A (en)
AU (12) AU2020398547C1 (en)
BR (2) BR112021025359A2 (en)
CA (4) CA3129193C (en)
CO (6) CO2021018203A2 (en)
IL (18) IL304390B2 (en)
MX (10) MX2022006759A (en)
MY (12) MY193349A (en)
NZ (6) NZ781143A (en)
PE (6) PE20221791A1 (en)
SG (6) SG11202110955VA (en)
TW (7) TW202128745A (en)
UA (1) UA129709C2 (en)
WO (7) WO2021112928A1 (en)
ZA (4) ZA202107644B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7235770B2 (en) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Formulations Containing High Concentrations of VEGF Receptor Fusion Proteins
AU2020208360B2 (en) * 2019-01-16 2025-05-08 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
KR20240007293A (en) * 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. Anti-vegf protein compositions and methods for producing the same
CN115803009A (en) 2020-05-08 2023-03-14 瑞泽恩制药公司 VEGF traps and microwells and methods for treating ocular diseases and cancer
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
AR127006A1 (en) * 2021-09-08 2023-12-06 Regeneron Pharma A HIGH-PERFORMANCE, MASS SPECTROMETRY-BASED METHOD FOR QUANTIFYING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CN116162148A (en) * 2021-11-24 2023-05-26 苏州光度生物科技有限公司 Multispecific ligand binding molecules and uses thereof
US20250223313A1 (en) * 2022-01-14 2025-07-10 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics
AU2023404729A1 (en) * 2022-12-01 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Trispecific fusion protein and use thereof
US12129499B2 (en) * 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof
KR20240115650A (en) 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 An amorphous nano molecule of tyrosine kinase inhibitors and containing composition and method for producing the same
WO2024206953A2 (en) * 2023-03-29 2024-10-03 Taktos Therapeutics Inc. Ides variant proteins and methods of using the same
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
EP0283942B1 (en) * 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (en) 1998-03-30 2003-04-15 Viranative Ab Nutritional medium containing methionine and its use
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
CN100523187C (en) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 Modified chimeric polyeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
WO2001039793A2 (en) * 1999-11-30 2001-06-07 Smithkline Beecham P.L.C. Pharmaceutical compositions containing sema7a polypeptides
MY136113A (en) 2000-05-26 2008-08-29 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
JP2005505240A (en) 2001-02-15 2005-02-24 セントカー・インコーポレーテツド Chemically synthesized medium for cultured mammalian cells
IL158328A0 (en) 2001-04-13 2004-05-12 Wyeth Corp Surface proteins of streptococcus pyogenes
WO2002101019A2 (en) 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
KR101088223B1 (en) 2002-12-23 2011-11-30 브리스톨-마이어스 스큅 컴퍼니 Product Quality Improvement in Mammalian Cell Culture Method for Protein Production
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (en) 2004-05-12 2009-09-09 华东理工大学 The serum free medium that a kind of suitable Chinese hamster ovary cell is cultivated
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006050050A2 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
HUE027096T2 (en) 2005-03-25 2016-08-29 Regeneron Pharma Vegf antagonist formulations
JP5427409B2 (en) 2005-06-09 2014-02-26 ハンサ メディカル アクチボラゲット Use of IdeS proteinase (derived from Streptococcus pyogenes) to treat autoimmune diseases and graft rejection
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN1778903A (en) 2005-09-29 2006-05-31 华东理工大学 A high-density continuous perfusion culture method for animal cells
SI2522717T1 (en) 2006-01-04 2014-05-30 Baxter International Inc. Oligopeptide-free cell culture media
CN100502945C (en) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Application of VEGF receptor fusion protein in the treatment of eye diseases
CN101478949A (en) 2006-06-16 2009-07-08 瑞泽恩制药公司 VEGF antagonist formulations suitable for intravitreal administration
HUE039128T2 (en) 2006-07-13 2018-12-28 Wyeth Llc Production of coagulation factor IX with improved glycosylation pattern
BRPI0716139A2 (en) * 2006-08-28 2013-09-17 Ares Trading Sa fc fusion protein purification process
AU2007294122B2 (en) 2006-09-10 2013-03-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
US20100113294A1 (en) 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
BRPI0815889A2 (en) 2007-08-31 2014-10-14 Hoffmann La Roche Glycosylation Profile Analysis.
CA2709029A1 (en) * 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
CN102112509B (en) 2008-07-31 2013-03-20 国立大学法人京都大学 Molding material containing unsaturated polyester resin and microfibrillated plant fiber
NZ591651A (en) 2008-09-26 2012-12-21 Merck Sharp & Dohme High titer antibody production and culture media comprising glucose, soy or wheat hydrolsyate, amino acids, and other chemical compounds
EP2435577A4 (en) 2009-05-26 2016-04-13 Momenta Pharmaceuticals Inc Production of glycoproteins
MX342623B (en) 2009-06-26 2016-10-06 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
WO2011014838A1 (en) 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
DK3037104T3 (en) * 2009-10-20 2020-07-20 Abbvie Inc ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A RELATED CHROMATOGRAPHY
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US8568250B2 (en) * 2010-07-07 2013-10-29 Nike, Inc. Golf ball with cover having zones of hardness
MX385629B (en) 2011-01-13 2025-03-18 Regeneron Pharma USE OF A VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONIST TO TREAT ANGIOGENIC OCULAR DISORDERS.
CN102653729B (en) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 Culture medium used for Chinese hamster ovary cells
WO2012140487A1 (en) 2011-04-11 2012-10-18 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
EP2702143B1 (en) 2011-04-29 2018-06-06 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
DK2702164T3 (en) 2011-04-29 2016-02-01 Biocon Res Ltd METHOD FOR REDUCING heterogeneity OF ANTIBODIES AND METHOD OF PRODUCING THESE ANTIBODIES
RU2661764C2 (en) 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Compositions and methods based on dac hyp
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
CA2951856A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (en) * 2012-06-07 2014-06-18 山东泉港药业有限公司 Method for purifying and preparing anti-VEGF antibody fragment
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
US9695416B2 (en) * 2012-07-18 2017-07-04 Siemens Healthcare Diagnostics Inc. Method of normalizing biological samples
CN104853763A (en) * 2012-08-02 2015-08-19 赛诺菲 Article of manufacture comprising aflibercept or ziv-aflibercept
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9365314B2 (en) * 2012-11-16 2016-06-14 Owens-Brockway Glass Container Inc. Product and package with a photosensitive use-evident feature
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (en) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 Animal source-free and serum-free culture medium of lymphocyte
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
BR112015021993A8 (en) 2013-03-15 2019-12-03 Genentech Inc polypeptide, methods for producing it, methods for culturing a cell, pharmaceutical composition, kit, and cell culture medium
ES2759061T3 (en) * 2013-03-15 2020-05-07 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl binding
CN103773732B (en) 2013-06-08 2016-05-11 李锋 The production technology of definite culture medium, its application and the large-scale culture mammalian cell of a kind of chemical composition
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104073464A (en) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 Serum-free CHO cell culture medium and preparation method thereof
AR101262A1 (en) 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
WO2016145307A1 (en) * 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
KR101867134B1 (en) * 2015-03-23 2018-06-12 한양대학교 산학협력단 Cell culture media for production of target material with high yield using mammalian cell, method for culturing cells and production of target material using the cell culture media
CA3208857A1 (en) 2015-04-01 2016-10-06 Boehringer Ingelheim International Gmbh Cell culture medium
CN105002242A (en) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 Serum-free culture medium for efficiently expressing recombinant human thyroid-stimulating hormone in CHO cells and application thereof
TWI797060B (en) 2015-08-04 2023-04-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
ES2913530T3 (en) 2015-08-12 2022-06-02 Novartis Ag Methods for treating ophthalmic disorders
JP6950957B2 (en) * 2015-10-22 2021-10-13 プロテノバ株式会社 Immunoglobulin-binding polypeptide
EP3377100B1 (en) * 2015-11-18 2025-02-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
JP2019501687A (en) 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Prefilled plastic syringe containing VEGF antagonist
CN105368808B (en) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 A kind of IdeS protease, preparation method and application
CN108602889A (en) 2015-12-22 2018-09-28 瑞泽恩制药公司 Cure the anti-CD20/ anti-cd 3 antibodies of bispecific of acute lymphoblastic leukemia
HRP20231156T1 (en) 2015-12-22 2024-01-05 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CN107025553A (en) * 2016-01-29 2017-08-08 上海新卡说信息技术有限公司 A kind of transaction processing method and transaction system
EP3436473A4 (en) * 2016-03-29 2019-10-23 Navya Biologicals Pvt. Ltd. A process for purification of fc-fusion proteins
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
CN106279412A (en) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 A kind of purification method of anti-VEGF class monoclonal antibody
SI3515487T1 (en) 2016-09-23 2023-09-29 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
TWI782930B (en) 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
GEP20237513B (en) * 2016-12-23 2023-06-12 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (en) 2017-04-26 2018-05-25 삼천당제약주식회사 Ophthalmic pharmaceutical composition
WO2018215580A1 (en) * 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP7097433B2 (en) * 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド How to purify glycosylated proteins from host cell galectin and other contaminants
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
CN111356471A (en) * 2017-11-20 2020-06-30 济世发展生物药业有限公司 Abutip formulation comprising lysine salt as tonicity modifier and use thereof
CN109929027B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Method for purifying recombinant fusion protein by linear elution step
CN109929038B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11667702B2 (en) * 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
JP7235770B2 (en) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Formulations Containing High Concentrations of VEGF Receptor Fusion Proteins
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
MX2021008983A (en) * 2019-01-30 2021-09-08 Amgen Inc AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZATION AND MODIFICATION THEREOF.
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (en) * 2019-07-08 2021-08-06 삼천당제약주식회사 Refining method of ophthalmic protein pharmaceuticals
KR20240007293A (en) * 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. Anti-vegf protein compositions and methods for producing the same

Also Published As

Publication number Publication date
US11098311B2 (en) 2021-08-24
CO2022000660A2 (en) 2022-01-28
MX2022006760A (en) 2023-01-30
AU2020398125B2 (en) 2022-12-15
AU2020396490C1 (en) 2023-04-27
US20220098280A1 (en) 2022-03-31
US20220227836A1 (en) 2022-07-21
IL288367B (en) 2022-10-01
AU2020397803C1 (en) 2023-05-11
IL288352B (en) 2022-11-01
US12012445B2 (en) 2024-06-18
US20210284684A1 (en) 2021-09-16
IL296512B2 (en) 2023-12-01
US20210206833A1 (en) 2021-07-08
CO2021018234A2 (en) 2022-01-17
PE20221789A1 (en) 2022-11-25
KR20250053206A (en) 2025-04-21
IL288351A (en) 2022-01-01
TW202128743A (en) 2021-08-01
US20230272044A1 (en) 2023-08-31
US20210214733A1 (en) 2021-07-15
IL288360B1 (en) 2023-05-01
CO2021018181A2 (en) 2022-01-17
US20220009998A1 (en) 2022-01-13
KR20220041083A (en) 2022-03-31
US20220127331A1 (en) 2022-04-28
EP4524147A3 (en) 2025-07-23
MY193355A (en) 2022-10-06
US20240317835A1 (en) 2024-09-26
US11180540B2 (en) 2021-11-23
US11472861B2 (en) 2022-10-18
MY193353A (en) 2022-10-06
KR20240005206A (en) 2024-01-11
US20230119662A1 (en) 2023-04-20
AU2020398547C1 (en) 2023-05-11
CA3172631A1 (en) 2021-06-10
IL304390B1 (en) 2025-01-01
US12012444B2 (en) 2024-06-18
IL288351B2 (en) 2024-05-01
US20220009997A1 (en) 2022-01-13
US20230068199A1 (en) 2023-03-02
JP2022550930A (en) 2022-12-06
NZ781136A (en) 2023-05-26
KR102519236B1 (en) 2023-04-10
SG11202110968VA (en) 2021-10-28
IL288367B2 (en) 2023-02-01
US20210171570A1 (en) 2021-06-10
BR112021025432A2 (en) 2022-06-21
CN114423783A (en) 2022-04-29
US11440950B2 (en) 2022-09-13
JP7681079B2 (en) 2025-05-21
US11732025B2 (en) 2023-08-22
AU2020397865C1 (en) 2023-04-27
PE20221788A1 (en) 2022-11-25
EP4524237A2 (en) 2025-03-19
IL288360A (en) 2022-01-01
CA3159586A1 (en) 2021-06-10
WO2021112924A1 (en) 2021-06-10
AU2020398547A1 (en) 2021-10-28
US20250034231A1 (en) 2025-01-30
US11098112B2 (en) 2021-08-24
IL309560B2 (en) 2025-05-01
CA3129193C (en) 2022-10-04
US20220033472A1 (en) 2022-02-03
MX2022012042A (en) 2022-10-27
CN114206907A (en) 2022-03-18
CA3172631C (en) 2024-01-02
IL302921A (en) 2023-07-01
EP3906250A1 (en) 2021-11-10
BR112021025158A2 (en) 2022-06-21
JP2024009950A (en) 2024-01-23
EP3931204A1 (en) 2022-01-05
IL309491B1 (en) 2025-02-01
US12319728B2 (en) 2025-06-03
AU2020397803A1 (en) 2021-10-28
WO2021112927A1 (en) 2021-06-10
MX2022011973A (en) 2022-11-09
EP3906302A1 (en) 2021-11-10
US20220227835A1 (en) 2022-07-21
KR20220038062A (en) 2022-03-25
AU2020398125A1 (en) 2021-10-28
US11485770B2 (en) 2022-11-01
MX2021014863A (en) 2022-09-28
BR112022001016A2 (en) 2022-08-16
MY190625A (en) 2022-04-27
EP4524236A3 (en) 2025-07-23
PE20221790A1 (en) 2022-11-25
US11505594B2 (en) 2022-11-22
US20220235116A1 (en) 2022-07-28
IL296893B1 (en) 2024-01-01
PE20221770A1 (en) 2022-11-11
TWI867028B (en) 2024-12-21
CN114206924A (en) 2022-03-18
AU2020398830C1 (en) 2023-04-27
KR20240007293A (en) 2024-01-16
IL288355B (en) 2022-11-01
IL304390B2 (en) 2025-05-01
AU2023201588B2 (en) 2025-06-26
US11186625B2 (en) 2021-11-30
IL318471A (en) 2025-03-01
US20230331812A1 (en) 2023-10-19
EP3931303A1 (en) 2022-01-05
US12202883B2 (en) 2025-01-21
AU2020398830A1 (en) 2021-10-28
EP4524236A2 (en) 2025-03-19
KR20220038348A (en) 2022-03-28
US11542317B1 (en) 2023-01-03
SG11202110955VA (en) 2021-10-28
KR20240005222A (en) 2024-01-11
ZA202208710B (en) 2024-09-25
US12054532B2 (en) 2024-08-06
US20210371501A1 (en) 2021-12-02
EP4524148A2 (en) 2025-03-19
JP2024119936A (en) 2024-09-03
KR20230051296A (en) 2023-04-17
IL296863B2 (en) 2023-10-01
KR102519234B1 (en) 2023-04-10
KR102619866B1 (en) 2024-01-04
CO2021018214A2 (en) 2022-01-17
US20220048975A1 (en) 2022-02-17
PE20221791A1 (en) 2022-11-25
IL317707A (en) 2025-02-01
IL288357B2 (en) 2023-03-01
SG11202110964QA (en) 2021-10-28
MY190686A (en) 2022-05-10
AU2020397803B2 (en) 2022-12-15
TW202128991A (en) 2021-08-01
IL309491A (en) 2024-02-01
US11104715B2 (en) 2021-08-31
IL309560A (en) 2024-02-01
SG11202110958QA (en) 2021-10-28
WO2021112925A1 (en) 2021-06-10
IL296893B2 (en) 2024-05-01
JP2024026116A (en) 2024-02-28
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
US20220033471A1 (en) 2022-02-03
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
KR20230152810A (en) 2023-11-03
NZ781137A (en) 2023-05-26
US11306135B2 (en) 2022-04-19
IL296512B1 (en) 2023-08-01
MY190627A (en) 2022-04-27
EP4524237A3 (en) 2025-07-09
AU2020397865A1 (en) 2021-10-28
IL296863B1 (en) 2023-06-01
AU2023201748A1 (en) 2023-06-01
AU2020396490B2 (en) 2022-12-15
EP4524148A3 (en) 2025-07-23
ZA202107646B (en) 2022-03-30
IL301888A (en) 2023-06-01
IL288357B (en) 2022-11-01
US20230041349A1 (en) 2023-02-09
JP2022548197A (en) 2022-11-17
US20220275054A1 (en) 2022-09-01
TW202134256A (en) 2021-09-16
MX2022006788A (en) 2022-07-11
AU2020397865B2 (en) 2022-12-15
US11407813B2 (en) 2022-08-09
WO2021112926A1 (en) 2021-06-10
US11753459B2 (en) 2023-09-12
TW202128744A (en) 2021-08-01
JP2023179531A (en) 2023-12-19
IL302538B1 (en) 2025-02-01
JP2022552052A (en) 2022-12-15
IL296512A (en) 2022-11-01
IL301888B1 (en) 2024-11-01
US11053280B2 (en) 2021-07-06
MX2023005421A (en) 2023-05-23
US11174283B2 (en) 2021-11-16
US20210206832A1 (en) 2021-07-08
IL288360B2 (en) 2023-09-01
AU2020398547B2 (en) 2022-12-22
CN114206914A (en) 2022-03-18
JP2022547652A (en) 2022-11-15
US11535663B2 (en) 2022-12-27
US11286290B2 (en) 2022-03-29
KR20220038349A (en) 2022-03-28
SG11202110953UA (en) 2021-10-28
JP2023171771A (en) 2023-12-05
KR20230051297A (en) 2023-04-17
TW202122417A (en) 2021-06-16
KR20220035393A (en) 2022-03-22
CN114206925A (en) 2022-03-18
IL296864B2 (en) 2023-10-01
US20230357357A1 (en) 2023-11-09
EP4516800A2 (en) 2025-03-05
NZ781143A (en) 2023-05-26
IL288357A (en) 2022-01-01
US20210171605A1 (en) 2021-06-10
AU2023201586A1 (en) 2023-04-13
US11548932B2 (en) 2023-01-10
IL301888B2 (en) 2025-03-01
IL302538A (en) 2023-07-01
AU2023201589A1 (en) 2023-04-06
MY193351A (en) 2022-10-06
TW202509053A (en) 2025-03-01
US12049489B2 (en) 2024-07-30
US12338274B2 (en) 2025-06-24
JP2022548818A (en) 2022-11-22
IL302538B2 (en) 2025-06-01
UA129709C2 (en) 2025-07-09
AU2023201590A1 (en) 2023-04-13
IL309560B1 (en) 2025-01-01
EP4516800A3 (en) 2025-07-09
IL288367A (en) 2022-01-01
MY193350A (en) 2022-10-06
AU2020398125C1 (en) 2023-05-11
US11505593B2 (en) 2022-11-22
MY190626A (en) 2022-04-27
US20220396608A1 (en) 2022-12-15
US20220162289A1 (en) 2022-05-26
US11958894B2 (en) 2024-04-16
IL302921B1 (en) 2025-05-01
ZA202107644B (en) 2022-03-30
JP2022547651A (en) 2022-11-15
JP2024009949A (en) 2024-01-23
US20230235019A1 (en) 2023-07-27
US11459373B2 (en) 2022-10-04
US20240309064A1 (en) 2024-09-19
EP4524147A2 (en) 2025-03-19
WO2021112923A1 (en) 2021-06-10
IL288351B1 (en) 2024-01-01
MX2022006758A (en) 2023-01-30
CA3172625A1 (en) 2021-06-10
CN114401994A (en) 2022-04-26
KR20220038347A (en) 2022-03-28
TW202128745A (en) 2021-08-01
CO2021018203A2 (en) 2022-01-17
US12054533B2 (en) 2024-08-06
US11649273B2 (en) 2023-05-16
WO2021112929A1 (en) 2021-06-10
ZA202107647B (en) 2022-03-30
BR112021025359A2 (en) 2022-06-21
US20210214430A1 (en) 2021-07-15
MX2021014862A (en) 2022-09-27
NZ781145A (en) 2023-05-26
IL288352A (en) 2022-01-01
MY190623A (en) 2022-04-27
CA3129193A1 (en) 2021-06-10
US20250197474A1 (en) 2025-06-19
AU2023201588A1 (en) 2023-04-13
AU2020398830B2 (en) 2022-12-15
CO2021018192A2 (en) 2022-01-17
IL309491B2 (en) 2025-06-01
TWI865587B (en) 2024-12-11
MX2023014077A (en) 2023-12-11
NZ781142A (en) 2023-05-26
JP2024167326A (en) 2024-12-03
IL296863A (en) 2022-11-01
EP3906249A1 (en) 2021-11-10
JP7673311B2 (en) 2025-05-08
PE20221261A1 (en) 2022-08-16
US20240294606A1 (en) 2024-09-05
MX2022006759A (en) 2023-01-30
BR112021025438A2 (en) 2022-06-21
MY190624A (en) 2022-04-27
US11299532B2 (en) 2022-04-12
BR112021025769A2 (en) 2022-04-12
US12077570B2 (en) 2024-09-03
IL296864B1 (en) 2023-06-01
IL288352B2 (en) 2023-03-01
WO2021112928A1 (en) 2021-06-10
US11459374B2 (en) 2022-10-04
AU2023201585A1 (en) 2023-04-13
IL288355A (en) 2022-01-01
AU2020396490A1 (en) 2021-10-28
EP3906303A1 (en) 2021-11-10
MY193354A (en) 2022-10-06
US20240067701A1 (en) 2024-02-29
IL304390A (en) 2023-09-01
US20220009999A1 (en) 2022-01-13
MY193349A (en) 2022-10-06
AU2023201590B2 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
IL288355A (en) Anti-vegf protein compositions and methods for producing the same
EP3802812A4 (en) Rna-targeting fusion protein compositions and methods for use
EP3773718A4 (en) Compositions and methods comprising anti-nrp2 antibodies
IL277797A (en) Methods for making stable protein compositions
GB202017593D0 (en) Compositions and methods and uses relating thereto
IL290331A (en) Rna-targeting ligands, compositions thereof, and methods of making and using the same
IL286587A (en) D-metyrosine compositions and methods for preparing same
IL285489A (en) Producing compositions comprising two or more antibodies
HK40057225A (en) Anti-vegf protein compositions and methods for producing the same
HK40055883A (en) Anti-vegf protein compositions and methods for producing the same
HK40055882A (en) Anti-vegf protein compositions and methods for producing the same
HK40055881A (en) Anti-vegf protein compositions and methods for producing the same
HK40055880A (en) Anti-vegf protein compositions and methods for producing the same
HK40057224A (en) Anti-vegf protein compositions and methods for producing the same
EP3858851A4 (en) Protein composition production method
TW202525842A (en) Anti-vegf protein compositions and methods for producing the same
HK40073147A (en) Cardiomyocytes and compositions and methods for producing the same
HK40062932A (en) Methods and compositions for protein sequencing
HK40100724A (en) Protein compositions and methods for producing and using the same
AU2021401316A1 (en) Protein compositions and methods for producing and using the same
HK40046593A (en) Compositions and methods comprising anti-nrp2 antibodies
GB202006922D0 (en) Compositions and methods and uses relating thereto
HK40042830A (en) Methods for making stable protein compositions
HK40050894A (en) Rna-targeting fusion protein compositions and methods for use
EP3638693A4 (en) Immunoglobulin compositions and process for obtaining the same